Evidence map›Paper›PMID 35802260›Full record

ReviewCellular and molecular life sciences : CMLS2022

The extra-cerebellar effects of spinocerebellar ataxia type 1 (SCA1): looking beyond the cerebellum.

Victor Olmos, Neha Gogia, Kimberly Luttik, Fatema Haidery, Janghoo Lim

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Victor OlmosDepartment of Genetics, Yale School of Medicine, 295 Congress Avenue, BCMM 154E, New Haven, CT, 06510, USA.
Neha GogiaDepartment of Genetics, Yale School of Medicine, 295 Congress Avenue, BCMM 154E, New Haven, CT, 06510, USA.
Kimberly LuttikInterdepartmental Neuroscience Program, Yale School of Medicine, 295 Congress Avenue, BCMM 154E, New Haven, CT, 06510, USA.
Fatema HaideryYale College, New Haven, CT, 06510, USA.
Janghoo LimDepartment of Genetics, Yale School of Medicine, 295 Congress Avenue, BCMM 154E, New Haven, CT, 06510, USA. janghoo.lim@yale.edu.ORCID http://orcid.org/0000-0002-5331-210X
Yale University · US

Funding

GENETICS AND GENOMICS OF HUMAN DISEASET32HD007149 · NICHD · YALE UNIVERSITY · PI James P Noonan · 1985 to 2026
$8.2M
NEUROBIOLOGY OF CORTICAL SYSTEMST32NS007224 · NINDS · YALE UNIVERSITY · PI CARDIN, JESSICA A · 1985 to 2025
$4.6M
Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseasesR01AG074609 · NIA · YALE UNIVERSITY · PI LIM, JANGHOO · 2021 to 2025
$4.0M
Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseasesR01AG076154 · NIA · YALE UNIVERSITY · PI Janghoo Lim · 2022 to 2026
$3.5M
Microglial regulation of Progranulin levelsR01AG066447 · NIA · YALE UNIVERSITY · PI LIM, JANGHOO · 2020 to 2024
$3.1M
Cellular and Molecular Studies of SBMA Neuromuscular DiseaseR01NS088321 · NINDS · YALE UNIVERSITY · PI LIM, JANGHOO · 2015 to 2019
$2.2M
Investigating the Pathogenesis of Cerebellar NeurodegenerationR01NS083706 · NINDS · YALE UNIVERSITY · PI LIM, JANGHOO · 2014 to 2018
$1.8M
Regulation of inhibitory interneuron developmentR21MH119803 · NIMH · YALE UNIVERSITY · PI LIM, JANGHOO · 2019 to 2020
$461k
NIA NIH HHS AG066447NIA NIH HHS AG074609NIA NIH HHS AG076154NIA NIH HHS R01 AG066447NIA NIH HHS R01 AG074609NIA NIH HHS R01 AG076154NICHD NIH HHS T32 HD007149NIMH NIH HHS MH119803NIMH NIH HHS R21 MH119803NINDS NIH HHS NS083706NINDS NIH HHS NS088321NINDS NIH HHS R01 NS083706NINDS NIH HHS R01 NS088321NINDS NIH HHS T32 NS007224Yale University Lo Graduate Fellowship for Excellence in Stem Cell Research
6 · The paper itself

Abstract

Spinocerebellar ataxia type 1 (SCA1) is one of nine polyglutamine (polyQ) diseases and is characterized as an adult late-onset, progressive, dominantly inherited genetic disease. SCA1 is caused by an increase in the number of CAG repeats in the ATXN1 gene leading to an expanded polyQ tract in the ATAXIN-1 protein. ATAXIN-1 is broadly expressed throughout the brain. However, until recently, SCA1 research has primarily centered on the cerebellum, given the characteristic cerebellar Purkinje cell loss observed in patients, as well as the progressive motor deficits, including gait and limb incoordination, that SCA1 patients present with. There are, however, also other symptoms such as respiratory problems, cognitive defects and memory impairment, anxiety, and depression observed in SCA1 patients and mouse models, which indicate that there are extra-cerebellar effects of SCA1 that cannot be explained solely through changes in the cerebellar region of the brain alone. The existing gap between human and mouse model studies of extra-cerebellar regions in SCA1 makes it difficult to answer many important questions in the field. This review will cover both the cerebellar and extra-cerebellar effects of SCA1 and highlight the need for further investigations into the impact of mutant ATXN1 expression in these regions. This review will also discuss implications of extra-cerebellar effects not only for SCA1 but other neurodegenerative diseases showing diverse pathology as well.

Indexed as

Spinocerebellar AtaxiasAnimalsCerebellumDisease Models, AnimalMicePurkinje CellsATXN1CerebellumNeurodegenerationPolyglutamineSpinocerebellar ataxia type 1

Identifiers

PMID35802260
PMCPMC9993484
OpenAlexW4284885104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.